Lifileucel Clinical Trials (2026): 10 Studies for Metastatic Melanoma & Unresectable Melanoma

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

10 Lifileucel clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 7 indications (including Metastatic Melanoma & Unresectable Melanoma) and 1,688 total planned enrollment. 2 Phase 3 Lifileucel trials and 5 Phase 2 are listed. 4 Lifileucel clinical trials are actively recruiting at 67 U.S. sites across 27 states. Most recent activity: NCT07288203 (Dec 2033).

Where to Participate: All Lifileucel Trial Sites in the U.S. (67 sites across 27 states)

Every actively recruiting Lifileuceltrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
ALUniversity of Alabama at Birmingham: The Kirklin ClinicBirmingham35233NCT05727904Map
AZHonor HealthPhoenix85016NCT06481592Map
AZMayo ClinicPhoenix85054NCT06743126Map
AZHonor Health Research InstituteScottsdale85258NCT06743126Map
CACity of HopeDuarte91010NCT05727904Map
CACity of Hope National Medical CenterDuarte91010NCT06743126Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT06743126Map
CAUCLA Hematology/OncologyLos Angeles90024NCT06743126Map
CAUniversity of Southern CaliforniaLos Angeles90007NCT06481592Map
CAUSC Norris Comprehensive Cancer CenterLos Angeles90007NCT05727904Map
CACalifornia Pacific Medical CenterSan Francisco94107NCT05727904Map
CAUCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco94143NCT06743126Map
CAStanford Cancer CenterStanford94305NCT06743126Map
COUniversity of Colorado Cancer CenterAurora80045NCT05727904Map
COUniversity of Colorado, Anschutz Medical CampusAurora80045NCT06743126Map
CTYale Cancer CenterNew Haven06510NCT06743126Map
FLUniversity of Miami - Sylvester Comprehensive Cancer CenteMiami33136NCT06743126Map
FLOrlando HealthOrlando32806NCT06481592Map
FLOrlando Health Cancer InstituteOrlando32806NCT05727904Map
FLH. Lee Moffitt Cancer Center and Research Institute, Inc.Tampa33612NCT06481592Map
FLMoffitt Cancer CenterTampa33612NCT06743126Map
GAAugusta UniversityAugusta30912NCT06481592Map
ILUniversity of Chicago Medical CenterChicago60637NCT06743126Map
KYUofL Health - Brown Cancer CenterLouisville40202NCT06481592Map
MDUniversity of MD Greenebaum Comprehensive Cancer CenterBaltimore21201NCT06743126Map
MDNational Cancer InstituteBethesda20814NCT05727904Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06743126Map
MAMassachusetts General HospitalBoston02114NCT06743126Map
MIUniversity of MichiganAnn Arbor48109NCT06743126Map
MIBarbara Ann Karmanos Cancer HospitalDetroit48201NCT06481592Map
MIHenry Ford HealthDetroit48202NCT05727904Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT06743126Map
NHDartmouth-Hitchcock Medical Center (DHMC) - Norris Cotton Cancer CenterLebanon03756NCT05727904Map
NJMD Anderson Cancer Center at CooperCamden08103NCT05727904Map
NJAtlantic Health System/Morristown Medical CenterMorristown07960NCT06743126Map
NYRoswell Park Cancer InstituteBuffalo14203NCT06481592Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT05607095Map
NYLaura and Isaac Perlmutter Cancer Center at NYU Langone HealthNew York10016NCT06743126Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06743126Map
NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)New York10065NCT05607095Map
NYUniversity of RochesterRochester14642NCT06743126Map
NCUNC Hospitals, The University of North Carolina at Chapel HillChapel Hill27599NCT06743126Map
OHOncology Hematology CareCincinnati45226NCT05727904Map
OHCleveland Clinic, Taussig Cancer InstituteCleveland44195NCT06743126Map
OHOhio State UniversityColumbus43201NCT05727904Map
OHOhio State UniversityColumbus43210NCT06743126Map
OKUniversity of OklahomaOklahoma City73117NCT06481592Map
ORProvidence Cancer Institute Franz ClinicPortland97213NCT06743126Map
PAFox Chase Cancer CenterPhiladelphia19111NCT06743126Map
PAThomas Jeffersion University, Sidney Kimmel Cancer CenterPhiladelphia19107NCT06743126Map
PAUniversity of Pennsylvania, Abramson Cancer CenterPhiladelphia19104NCT06743126Map
PAAllegheny HealthPittsburgh15524NCT06481592Map
PAAllegheny Health NetworkPittsburgh15224NCT05727904Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT06743126Map
SDAvera Cancer InstituteSioux Falls57105NCT06743126Map
SDAvera Medical Group OncologySioux Falls57105NCT06481592Map
TNBaptist Cancer CenterBartlett37920NCT05727904Map
TNSCRI Oncology PartnersNashville37203NCT05727904Map
TNSCRI Oncology PartnersNashville37203NCT06743126Map
TXBaylor UniversityDallas75246NCT06743126Map
TXUniversity of Texas Southwestern Medical CenterDallas75390NCT06743126Map
TXMD Anderson Cancer Center - U of TexasHouston77030NCT06481592Map
TXThe University of Texas MD Anderson Cancer CenterHouston77030NCT06743126Map
UTHuntsman Cancer Institute, University of UtahSalt Lake City84112NCT06743126Map
VAVirginia Commonwealth UniversityRichmond23219NCT06743126Map
WASwedish Cancer InstituteEdmonds98026NCT05727904Map
WAFred Hutchinson Cancer CenterSeattle98109NCT06743126Map

Lifileucel clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingcompletedterminatedTotal
P1123
P211215
P322

Recruiting Lifileucel clinical trials (4)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT06743126SUPRAMESUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaP3Melanoma, Cutaneous Malignant360Jan 2025
NCT05727904Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.P3Metastatic Melanoma670Mar 2023
NCT06481592A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.P2Endometrial Cancer60Oct 2024
NCT05607095A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated LiposarcomaP1Uveal Melanoma30Nov 2022

Lifileucel clinical trials by indication

Metastatic Melanoma (4)

NCTAcronymPhaseStatusTitle
NCT05727904P3recruitingStudy to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05640193P1active not recruitingA Study of LN-144 in People With Metastatic Melanoma to the Brain
NCT03645928P2terminatedStudy of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
NCT02360579LN-144P2completedStudy of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Melanoma (Skin Cancer) (1)

NCTAcronymPhaseStatusTitle
NCT07288203P2active not recruitingA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Melanoma, Cutaneous Malignant (1)

NCTAcronymPhaseStatusTitle
NCT06743126SUPRAMEP3recruitingSUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Endometrial Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06481592P2recruitingA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

Clinical Stage IV Cutaneous Melanoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT06151847P2completedLifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Uveal Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT05607095P1recruitingA Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

Locally Advanced Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT05176470P1active not recruitingNeoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Lifileucel pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
SUPRAMENCT06743126P3recruitingMelanoma, Cutaneous Malignant360
LN-144NCT02360579P2completedMetastatic Melanoma220

Terminated and withdrawn Lifileucel trials (1)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

All Lifileucel trials (10)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT07288203A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaP2active not recruiting100Iovance Biotherapeutics, Inc.Nov 2025
NCT06743126SUPRAMESUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaP3recruiting360Immatics US, Inc.Jan 2025
NCT05727904Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.P3recruiting670Iovance Biotherapeutics, Inc.Mar 2023
NCT06481592A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.P2recruiting60Iovance Biotherapeutics, Inc.Oct 2024
NCT05607095A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated LiposarcomaP1recruiting30Memorial Sloan Kettering Cancer CenterNov 2022
NCT05176470Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma PatientsP1active not recruiting2Richard WuJul 2022
NCT05640193A Study of LN-144 in People With Metastatic Melanoma to the BrainP1active not recruiting10Memorial Sloan Kettering Cancer CenterNov 2022
NCT03645928Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsP2terminated225Iovance Biotherapeutics, Inc.May 2019
NCT06151847Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic MelanomaP2completed11University of Kansas Medical CenterDec 2023
NCT02360579LN-144Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaP2completed220Iovance Biotherapeutics, Inc.Sep 2015

Lifileucel clinical trials: frequently asked questions

How many Lifileucel clinical trials are there?
10 Lifileucel clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants. 2 are marked completed.
Are Lifileucel clinical trials recruiting in 2026?
Yes — 4 Lifileucel trials are actively recruiting in 2026, with 67 U.S. sites across 27 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Lifileucel being studied for?
Lifileucel is being studied for Metastatic Melanoma, Unresectable Melanoma, Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Melanoma, Cutaneous Malignant and 11 more. The trials are grouped by indication on this page.
What phase is Lifileucel in?
Lifileucel clinical trials span 2 Phase 3, 5 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Lifileucel clinical trials?
The lead sponsor across the most Lifileucel trials is Iovance Biotherapeutics, Inc., with 4 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Lifileucelas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: